Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Non-Current Liabilities (2024 - 2025)

Rein Therapeutics filings provide 2 years of Total Non-Current Liabilities readings, the most recent being $7.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 3.74% year-over-year to $7.2 million, compared with a TTM value of $7.2 million through Dec 2025, down 3.74%, and an annual FY2025 reading of $7.2 million, down 3.74% over the prior year.
  • Total Non-Current Liabilities hit $7.2 million in Q4 2025 for Rein Therapeutics, down from $7.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $9.5 million in Q2 2025, with the low at $7.2 million in Q4 2025.